Jefferies analyst Chris Howerton downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Hold and announces $57 price target.
Daiichi Sankyo Q2 Sales ¥327.50B Up From ¥280.30B YoY. The Company Reports Net Profit Of ¥39.5B Up From ¥18.9B YoY
Daiichi Sankyo (OTC:DSNKY) reported ¥327.50 billion in sales this quarter. This is a 16.84 percent increase over sales of ¥280.30 billion in the same period last year.